u/Avish_Golakiya · 35d ago14 prior · awaiting results
10 penny biotechs I'm watching for August 2026, and adding slowly
Altimmune has a 45-month cash runway (no dilution risk) and 46% short float while testing pemvidutide (GLP-1/glucagon dual agonist) in alcohol use disorder—a less-crowded indication than obesity/MASH. Three insider open-market buys into heavy short interest suggest conviction by informed investors.
Now $3.403m ago